1. Home
  2. SPRU vs RNTX Comparison

SPRU vs RNTX Comparison

Compare SPRU & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRU
  • RNTX
  • Stock Information
  • Founded
  • SPRU 2008
  • RNTX 2001
  • Country
  • SPRU United States
  • RNTX United States
  • Employees
  • SPRU N/A
  • RNTX N/A
  • Industry
  • SPRU Auto Parts:O.E.M.
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPRU Consumer Discretionary
  • RNTX Health Care
  • Exchange
  • SPRU Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • SPRU 34.9M
  • RNTX 40.3M
  • IPO Year
  • SPRU N/A
  • RNTX N/A
  • Fundamental
  • Price
  • SPRU $1.55
  • RNTX $1.11
  • Analyst Decision
  • SPRU
  • RNTX
  • Analyst Count
  • SPRU 0
  • RNTX 0
  • Target Price
  • SPRU N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • SPRU 3.8M
  • RNTX 57.4K
  • Earning Date
  • SPRU 08-11-2025
  • RNTX 08-13-2025
  • Dividend Yield
  • SPRU N/A
  • RNTX N/A
  • EPS Growth
  • SPRU N/A
  • RNTX N/A
  • EPS
  • SPRU N/A
  • RNTX N/A
  • Revenue
  • SPRU $87,638,000.00
  • RNTX N/A
  • Revenue This Year
  • SPRU $2.12
  • RNTX N/A
  • Revenue Next Year
  • SPRU N/A
  • RNTX N/A
  • P/E Ratio
  • SPRU N/A
  • RNTX N/A
  • Revenue Growth
  • SPRU 9.48
  • RNTX N/A
  • 52 Week Low
  • SPRU $1.13
  • RNTX $1.04
  • 52 Week High
  • SPRU $3.35
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • SPRU 56.10
  • RNTX N/A
  • Support Level
  • SPRU $1.13
  • RNTX N/A
  • Resistance Level
  • SPRU $1.32
  • RNTX N/A
  • Average True Range (ATR)
  • SPRU 0.13
  • RNTX 0.00
  • MACD
  • SPRU 0.03
  • RNTX 0.00
  • Stochastic Oscillator
  • SPRU 67.74
  • RNTX 0.00

About SPRU Spruce Power Holding Corporation

Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: